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a b s t r a c t
Background: There are scarce data regarding the signiﬁcance of the tumor size, hormonal
activity and size of the pituitary tumor of the young; therefore, the study was designed to
deﬁne the relation of the hormonal status of the large pituitary adenomas.
Objective: We compared those features with tumors of the elderly (>40) with the young
patients, and analyzed the clinicopathologic and proliferative features of pituitary macro-
adenomas in young adulthood (≤40).
Methods: 20-year archives of pituitary tumors in our clinics were reviewed and macroade-
nomas with diameter ≥3 cm were included in the study. We identiﬁed 46 pituitary adenomas
and immunohistochemically stained them with pituitary hormones, p53 and Ki-67. Twenty-
four cases were ≤40-year with an age range of 11–40 years (mean 28.0). Twenty-two cases
were >40 with an age range of 44–78 years (mean 58.8).
Results: In the young patient group, 15 (62.5%) were functional adenomas (6 prolactinomas,
six growth hormone [GH], one adrenocorticotrophic hormone [ACTH] adenoma, two multi-
hormonal [GH + ACTH]) and nine (37.5%) were either gonadotrophic or null cell adenomas.
In the elderly group, ﬁve (22.7%) were functional adenomas (two adrenocorticotrophic
hormone [ACTH] adenoma, one prolactinoma, one growth hormone [GH], one multihormo-
nal [GH + ACTH]) and 17 (77.3%) were either gonadotrophic or null cell adenomas. Ki-67
proliferation index in adenomas of the young was approximately two-folds higher than the
elderly (2.7% vs. 1.2%).
Conclusion: In both groups, rare p53 positivity was identiﬁed. In conclusion, pituitary macro-
adenomas of the young show hormonal expression frequently with relatively high Ki-67
proliferation indices.
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Most of pituitary adenomas are benign but some grow rapidly,
spreading to extrasellar tissues and present neurological
symptoms similar to other intracranial neoplasms [1]. Although
the deﬁnition and clinical signiﬁcance is not clear, some authors
describe it as ‘‘the giant pituitary adenoma’’ [1–3].
The term 'giant adenoma' is arbitrarily based on size alone.
However, these big sized tumors usually had tendency to invade
cavernous sinus, sphenoid sinus, and vasculature. In our series
of pituitary adenomas, using the preoperative computerized
tomography (CT) and magnetic resonance imaging (MRI)
studies, we differentiated the tumors with diameter >3 cm,
and then classiﬁed them into two groups in regard to the age of
the patients (age ≤40 and >40) in order to identify proliferative
features and immunohistochemical hormonal status of large
pituitary adenomas particularly in young patients (≤40) and
compare them with the results of the elderly (>40).
2. Materials and methods
Cases operated between 1991 and 2011 were retrospectively
retrieved from the archives of Departments of Pathology and
Neurosurgery, Gülhane Military Medical Academy. Data from
records of the authors (BD and EG) were assessed to obtain
clinical features and the information regarding the size of
pituitary adenomas. Forty-six cases with a pituitary adenoma
sizing over 3 cm in a single plane on preoperative images were
identiﬁed (Figs. 1 and 2). Tissue specimens were totally
submerged and ﬁxed in 10% buffered formalin. Tissues were
processed routinely, cut into 4 mm thick sections, and stained
with hematoxylin–eosin and reticulin.
2.1. Immunohistochemical study
All archival tissue blocks from each case were initially
checked by hematoxylin–eosin stained sections to selectFig. 1 – Sagittal T1 enhanced preoperative (on the left) and postop
tumor of approximately 4 cm in diameter.the representative block with available tissue for immunohis-
tochemical labeling. A 4 mm thick section from each formalin-
ﬁxed and parafﬁn-embedded tumor was stained using the
primary antibody against prolactin, growth hormone, adreno-
corticotropic hormone, follicle-stimulating hormone, luteiniz-
ing hormone, thyroid-stimulating hormone, (all monoclonal,
1:100; Cell Marque, Rocklin, CA), Ki-67 (clonal, 1:100; Neomar-
kers, Fremont, CA, USA) and p53 (clonal, 1:100; Santa Cruz
Biotechnology, Santa Cruz, CA, USA). Immunohistochemistry
was performed automatically (Ventana, Tucson, AZ, USA)
using ultraview universal DAB detection kit (Roche Diagnostics
GmbH, Mannheim, Germany).
2.2. Evaluation of immunohistochemistry
All immunohistochemically labeled slides of p53 and Ki-67
were manually counted (Figs. 3 and 4). Initially, immunohis-
tochemically stained slides were scanned at low power and
then the most intensely stained area was selected to count
the positive cells. One thousand cells were counted for each
analysis using an ocular grid. The percentage of positive cells
was calculated by comparing the number of positive stained
cells to total number.
The research protocol was approved by the ethical
committee of Gülhane Military Medical Academy.
3. Results
There were 46 patients in the study (15 female, 31 male) and
overall mean age was 42.7 years (median 40, range 11–78).
Patients were classiﬁed into two groups as young adulthood
(≤40) and elderly (>40). Of all patients involved in the study, 20
(43.5%) pituitary adenomas were hormone-active.
In the young adulthood group, there were twenty-four
cases (4 female, 20 male) with a mean age of 28 (range 11–40).
Of the young patients, 15 (62.5%) had functional adenomas
that consisted of 6 prolactinomas, 6 growth hormone
[GH] secreting adenomas, two multihormonal [GH + ACTH]erative (on the right) MR image of the patient with a pituitary
Fig. 2 – Coronal T1 enhanced preoperative and postoperative MR images of the same patient.
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[ACTH] adenoma. Of the young patients, 9 (37.5%) had either
gonadotrophic or null cell adenomas.
In the elderly group, there were twenty-two cases (11
female, 11 male) with a mean age of 58.8 ranging from 44 to 78.
Five (22.7%) were functional adenomas, which consisted of two
adrenocorticotrophic hormone (ACTH) adenomas, one pro-
lactinoma, one growth hormone (GH), and one multihormonal
(GH + ACTH) adenoma. Of the elderly, 17 (77.3%) were either
gonadotrophic or null cell adenomas.
Overall, mean Ki-67 proliferation index of all macroade-
nomas in the study was 1.9% (range 0.1–8%). Ki-67 proliferation
index in adenomas of young adulthood was approximately
two-folds higher than the elderly (2.7% vs. 1.2%).
Overall, the mean percentage of p53 positivity of all
macroadenomas in the study was 0.9% (range 0–10%). Except
one patient with prolactinoma, all of the cases had p53
positivity less than 10% in the young patient group.
4. Discussion
Pituitary tumors constitute 8–12% of all intracranial neo-
plasms, but they are uncommon in the young and even rare
in childhood [3]. In the literature, there are no series of largeFig. 3 – HE stained sections (left) were examined and the ones w
detection (prolactin) (second on the left) and further immunohist
indices and p53 expressions (right square).pituitary macroadenomas or giant adenomas in young
patients that present their proliferative characteristics and
compare them with the large adenomas of the elderly. Some
studies consist of surgically and medically treated micro- and
macroadenomas in young patients and present their clinical,
endocrine features and surgical outcomes. In the present
study, we focused on surgically treated large (>3 cm) pituitary
adenomas of young adults. The available tissue enabled us to
study the proliferative index and p53 status of tumor and
compare them with the large adenomas of the elderly in our
series (Table 1).
Pituitary adenomas diagnosed in patients at the age of 21
and younger were frequently hormonally active (80–97%) [1–3].
Nearly two-thirds of the functional adenoma cases were
diagnosed as prolactinomas. Pandey et al. reported that the
95.2% of the patients under 18 years old who were operated for
pituitary tumors had functioning adenomas, where 47.6%
of them were prolactinomas [3]. These patients typically
presented with endocrine symptoms related to their adenoma
type. Considering all pituitary micro- and macro-adenomas
in young patients, prolactinoma is the most common one. In
their series, Pandey et al. included 72.1% macroadenomas and
9.3% giant adenomas. Higher percentage of visual deteriora-
tion (65.1%) compared to the published data in the literature is
attributable to the large number of sizable adenomas in theirith remarkable tumor tissue were selected for hormone
ochemical procedures for Ki 67 (3rd on the left) proliferation
Fig. 4 – Growth hormone was studied on this slice that was known to be a GH secreting tumor specimen. Third picture from
the left and right square reflect the immunohistochemical reflections of Ki67 proliferation index and p53 expression,
respectively.
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functioning tumors at the age of 21 or younger [1]. Again
consistent with the previously published available data, 71%
of the hormonally active tumors were diagnosed as prolactino-
mas [1]. Cannavo et al. reported corroborative data about the
hormonally active pituitary macroadenoma and microadenoma
rates of 78% and 82%, respectively. Overall, 68% of them were
prolactin-secreting tumors. In contrast, around one-third of the
adult pituitary adenomas are non-functioning, and as the size of
the tumors increases, percentage of non-functioning tumors
rises [4]. The frequency of GH adenomas among the micro- and
macroadenomas of children and young patients was reported as
7% in Cannavo's series. Steele et al. reported only one patient
with GH secreting adenoma among 41 (2.4%) pituitary tumor
cases in their series [1], where Pandey et al. reported 21.4% (9 in
42 cases) [3]. The frequency of non-functioning tumors among
young pituitary adenomas is negligible.
On the other hand, there are several series of giant pituitary
adenomas, which comply with young and elder patients. Their
average age ranged between 36.8 and 47.9 [4,5]. Most of the
giant adenomas are non-functioning and present with visual
ﬁeld deﬁcits. Among the functioning giant pituitary adeno-
mas, prolactinomas and GH adenomas are detected most
frequently [1–6].
In the present study of large pituitary adenomas of young
adults, 62.5% of functional (gonadotrophic cell adenomas wereTable 1 – Immunohistochemical subtypes, Ki-67 proliferation i
(>3 cm) in young adulthood and elderly.
Young adulthood 
n: 24
Mean age (range) 28.0 (11–40
Male/Female 20/4 
Functional adenomas 15 (62.5%) 
Prolactinoma 6 (25.0%) 
GH adenoma 6 (25.0%) 
ACTH adenoma 1 (4.2%) 
Multihormonal (GH + ACTH) 2 (8.3%) 
Non-functioning adenomas 9 (37.5%) 
Ki-67 proliferation index, mean (range) 2.7% (0.1–8
p53 expression, mean (range) 1.6% (0–10%
GH: growth hormone; ACTH: adrenocorticotrophic hormone.included in the non-functioning portion) large pituitary
macroadenomas were differentiated. Distribution of the
functional macroadenomas in our series corroborated the
data in the literature. The frequency of prolactinoma was 25%.
They were all male patients as our institution serves a
heterogeneous population of patients that usually comprises
young male adults in their twenties. On the other hand, GH
adenomas (25%) were also as frequent as prolactinomas. In our
series, pathologic diagnosis yielded 37.5% non-functioning
adenomas, half of which consisted of gonadotrophic cell
adenomas. Most of the patients were older than 30 years.
In a few studies of giant pituitary adenomas, MIB-1 or Ki-67
indices were investigated [5]. In order to establish the
clinicopathologic and immunohistochemical features for
giant pituitary adenomas, Chacko et al. studied vascular
endothelial growth factor, microvessel density (MVD), topo-
isomerase and MIB-1 immunohistochemically in 28 cases of
pituitary adenomas with diameter of 5 cm or more [4]. They
found that the MIB-1 labeling index (LI) ranged from 0.1% to
2.4% with a mean value of 0.67%. No tumor showed a MIB-1 LI
greater than 3%. Furthermore, mean MIB-1 LI did not differ
signiﬁcantly between hormonal subtypes. In addition, our
gonadotrophic adenoma rates kept up with the rate that
Chacko et al. reported. They concluded that the giant pituitary
adenomas, which they particularly described as those over






) 58.8 (41–78) 42.7 (11–78)
11/11 31/15
5 (22.7%) 20 (43.5%)
1 (4.5%) 7 (15.3%)
1 (4.5%) 7 (15.3%)
2 (9.1%) 3 (6.5%)
1 (4.5%) 3 (6.5%)
17 (77.3%) 26 (56.5%)
%) 1.2% (0.1–3.5%) 1.9% (0.1–8%)
) 0.4% (0–2.7%) 0.9% (0–10%)
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phic adenomas in subtype most of the time [4].
In a series of 17 pituitary adenomas having a diameter of
>4 cm, by using immunohistochemistry, Madsen et al. focused
on any potential role for p53 and MIB-1, features alleged to be
associated with atypical adenomas [5]. They compared those
ﬁndings with non-giant, non-invasive gonadotrophic and null
cell adenomas. In their study, while MIB-I labeling indices in
non-giant adenomas ranged from 0.5% to 3.0% (mean 1.3%),
the same entities in giant tumors showed a broad range of 0.6–
6.5% with a mean value of 2.7%. Immunoreactivity for p53 was
<3% in all cases of giant adenomas with a mean of 0.6%.
Despite the aggressive features of massive size and cavernous
sinus invasion, immunohistochemical labeling for p53 and
MIB-1 were minimally increased. Their ﬁndings emphasized
that, in predicting the tumor biology and behavior, it was more
important to differentiate the adenoma type by IHC to
determine the subtype of the hormone, rather than MIB-I LI
and p53 immunostaining [5].
In the present study, the mean Ki-67 index in large
adenomas of young patients was approximately two-folds
higher than that of the elderly (2.7% vs. 1.2%). However, the Ki-
67 indices in the young showed a wide range from 0.1% to 8%.
Moreover, considerable overlap was present between young
and elderly for the Ki-67 indices. No statistically signiﬁcant
difference was observed between groups for Ki-67 proliferation
indices. To wrap up, our results concur with that of the
published literature implying that most non-functioning giant
pituitary adenomas are long standing, slow growing and
immunohistochemical expressions do not signiﬁcantly corre-
late with invasive behavior overall. More research is needed to
determine other speciﬁc factors that indicate invasiveness in
pituitary adenomas.
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